Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have earned an average rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $32.17.
Several research firms have recently weighed in on ANVS. EF Hutton Acquisition Co. I raised shares of Annovis Bio to a “strong-buy” rating in a report on Tuesday, August 13th. Maxim Group raised shares of Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annovis Bio in a report on Wednesday, October 16th.
Read Our Latest Stock Analysis on ANVS
Institutional Trading of Annovis Bio
Annovis Bio Trading Down 2.0 %
NYSE ANVS opened at $9.56 on Monday. The firm has a market cap of $124.73 million, a price-to-earnings ratio of -1.87 and a beta of 1.72. The company has a 50 day moving average of $8.59 and a 200-day moving average of $8.51. Annovis Bio has a 1-year low of $4.53 and a 1-year high of $22.49.
Annovis Bio (NYSE:ANVS – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. On average, analysts forecast that Annovis Bio will post -2.53 earnings per share for the current year.
About Annovis Bio
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Read More
- Five stocks we like better than Annovis Bio
- Stock Average Calculator
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What Does a Stock Split Mean?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Healthcare Dividend Stocks to Buy
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.